KR101848527B1 - 생물학적 유체 내 중간 및 단백질 결합 요독의 함량 측정 방법 및 장치 - Google Patents
생물학적 유체 내 중간 및 단백질 결합 요독의 함량 측정 방법 및 장치 Download PDFInfo
- Publication number
- KR101848527B1 KR101848527B1 KR1020137002066A KR20137002066A KR101848527B1 KR 101848527 B1 KR101848527 B1 KR 101848527B1 KR 1020137002066 A KR1020137002066 A KR 1020137002066A KR 20137002066 A KR20137002066 A KR 20137002066A KR 101848527 B1 KR101848527 B1 KR 101848527B1
- Authority
- KR
- South Korea
- Prior art keywords
- concentration
- wavelength
- biological fluid
- range
- dialysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 86
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 38
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 38
- 239000013060 biological fluid Substances 0.000 title claims abstract description 30
- 239000002441 uremic toxin Substances 0.000 title description 2
- 230000003287 optical effect Effects 0.000 claims abstract description 42
- -1 phosphoryl sulphate sulfate Chemical compound 0.000 claims abstract description 14
- 230000003595 spectral effect Effects 0.000 claims abstract description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 45
- 238000005259 measurement Methods 0.000 claims description 43
- 239000004202 carbamide Substances 0.000 claims description 27
- 230000005284 excitation Effects 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 230000008030 elimination Effects 0.000 claims description 7
- 238000003379 elimination reaction Methods 0.000 claims description 7
- 238000012545 processing Methods 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 5
- LMFWXTZEFKLNSB-UHFFFAOYSA-N OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.P.P Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.P.P LMFWXTZEFKLNSB-UHFFFAOYSA-N 0.000 claims description 4
- 238000004422 calculation algorithm Methods 0.000 claims description 3
- 238000013079 data visualisation Methods 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 238000004364 calculation method Methods 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 238000004611 spectroscopical analysis Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 abstract description 48
- 108010081355 beta 2-Microglobulin Proteins 0.000 abstract description 48
- 235000013877 carbamide Nutrition 0.000 abstract description 21
- 239000000385 dialysis solution Substances 0.000 abstract description 20
- 150000003672 ureas Chemical class 0.000 abstract description 3
- 230000034512 ubiquitination Effects 0.000 abstract 1
- 238000010798 ubiquitination Methods 0.000 abstract 1
- 238000000502 dialysis Methods 0.000 description 72
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 35
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 24
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 16
- 239000003617 indole-3-acetic acid Substances 0.000 description 16
- 239000000126 substance Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 11
- 230000002685 pulmonary effect Effects 0.000 description 10
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 9
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 9
- 229940116269 uric acid Drugs 0.000 description 9
- 229940109239 creatinine Drugs 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 208000037157 Azotemia Diseases 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 208000009852 uremia Diseases 0.000 description 7
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 4
- 238000002189 fluorescence spectrum Methods 0.000 description 4
- 238000001631 haemodialysis Methods 0.000 description 4
- 230000000322 hemodialysis Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229910021653 sulphate ion Inorganic materials 0.000 description 4
- 229930192334 Auxin Natural products 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 206010002022 amyloidosis Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000002363 auxin Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 229940045136 urea Drugs 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- DMBATUWDSVJGGB-UHFFFAOYSA-N CCCCCCCCCCCCOS(O)(=O)=O.CCCCCCCCCCCCOS(O)(=O)=O.CCCCCCCCCCCCOS(O)(=O)=O.P Chemical compound CCCCCCCCCCCCOS(O)(=O)=O.CCCCCCCCCCCCOS(O)(=O)=O.CCCCCCCCCCCCOS(O)(=O)=O.P DMBATUWDSVJGGB-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 description 2
- 238000004497 NIR spectroscopy Methods 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 231100000567 intoxicating Toxicity 0.000 description 2
- 230000002673 intoxicating effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 239000003375 plant hormone Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- ZGCHLOWZNKRZSN-NTSWFWBYSA-N 3-deoxyglucosone Chemical compound OC[C@@H](O)[C@@H](O)CC(=O)C=O ZGCHLOWZNKRZSN-NTSWFWBYSA-N 0.000 description 1
- UHPMJDGOAZMIID-UHFFFAOYSA-N 3-deoxyglucosone Natural products OCC1OC(O)C(=O)CC1O UHPMJDGOAZMIID-UHFFFAOYSA-N 0.000 description 1
- 206010003226 Arteriovenous fistula Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 238000010989 Bland-Altman Methods 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 238000012773 Laboratory assay Methods 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000016463 Wild type ABeta2M amyloidosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007813 chromatographic assay Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 108010088383 interleukin-6 receptor alpha Proteins 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000004793 poor memory Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EEP201000056A EE05676B1 (et) | 2010-06-28 | 2010-06-28 | Optiline meetod ja seade keskmise suurusega ja valkudega seotud ureemiliste toksiinide mramiseks bioloogilistes vedelikes |
| EEP201000056 | 2010-06-28 | ||
| EEP201000085 | 2010-12-10 | ||
| EEP201000085A EE05669B1 (et) | 2010-12-10 | 2010-12-10 | Optiline meetod ja seade keskmise suurusega ja valkudega seotud ureemiliste toksiinide mramiseks bioloogilistes vedelikes |
| PCT/EE2011/000008 WO2012000521A1 (en) | 2010-06-28 | 2011-06-28 | A method and device for determining content of the middle and protein bound uremic toxins in a biological fluid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20130038347A KR20130038347A (ko) | 2013-04-17 |
| KR101848527B1 true KR101848527B1 (ko) | 2018-04-12 |
Family
ID=44508544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137002066A Active KR101848527B1 (ko) | 2010-06-28 | 2011-06-28 | 생물학적 유체 내 중간 및 단백질 결합 요독의 함량 측정 방법 및 장치 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9103789B2 (enExample) |
| EP (1) | EP2585830B1 (enExample) |
| JP (1) | JP5957450B2 (enExample) |
| KR (1) | KR101848527B1 (enExample) |
| CN (1) | CN102985822A (enExample) |
| AU (1) | AU2011274009B2 (enExample) |
| BR (1) | BR112012033625A2 (enExample) |
| CA (1) | CA2837488C (enExample) |
| NZ (1) | NZ605685A (enExample) |
| WO (1) | WO2012000521A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102012112790A1 (de) * | 2012-12-20 | 2014-06-26 | B. Braun Avitum Ag | Verfahren und Vorrichtung zur Bestimmung von Abfallprodukten wie Indoxyl Sulfate in der Dialyse |
| US10150983B2 (en) * | 2013-02-19 | 2018-12-11 | Nipro Corporation | Method for measuring indoxyl sulfuric acid |
| CN104991026A (zh) * | 2015-06-29 | 2015-10-21 | 苏州东辰林达检测技术有限公司 | 尿液中甲基马尿酸的检测方法 |
| EP3537135A1 (en) * | 2018-03-05 | 2019-09-11 | Tallinn University of Technology | A device and method for assessment of a concentration of free pentosidine in a spent dialysate |
| JP7207702B2 (ja) * | 2018-11-06 | 2023-01-18 | 国立研究開発法人農業・食品産業技術総合研究機構 | 成分抽出方法、蛍光指紋測定装置、及びコンピュータが実行可能なプログラム |
| GB202104698D0 (en) * | 2021-03-31 | 2021-05-12 | Tallinn Univ Of Technology | Multiparametric optical method and apparatus for the determination of uremic solutes, including uremic toxins, in biological fluids |
| TWI838830B (zh) * | 2022-04-08 | 2024-04-11 | 財團法人工業技術研究院 | β2-微球蛋白濃度的分析方法及裝置 |
| CN120948421A (zh) * | 2025-10-15 | 2025-11-14 | 天津医科大学 | 一种定量-判别一体化尿毒症智能检测系统 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010053556A1 (en) | 1998-05-08 | 2001-12-20 | Anderson Charles W. | Miniature immuno-optical rapid analyte sensor platform |
| US20030231294A1 (en) | 2002-06-12 | 2003-12-18 | Ramesh Wariar | Optical sensor and method for measuring concentration of a chemical constituent using its intrinsic optical absorbance |
| US20060170914A1 (en) * | 2003-07-03 | 2006-08-03 | Wako Pure Chemical Industries, Ltd. | Specific component measuring method by spectral measurement |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3261264B2 (ja) | 1994-07-13 | 2002-02-25 | 株式会社堀場製作所 | 多成分水溶液の分析方法およびその分析装置 |
| WO1998019592A1 (en) * | 1996-11-01 | 1998-05-14 | Rio Grande Medical Technologies, Inc. | Dialysis monitoring method and apparatus |
| SE525639C2 (sv) | 1998-06-04 | 2005-03-22 | Thore Falkvall | Bestämning av slaggprodukter i dialysvätska med hjälp av optisk sensor |
| AUPR748501A0 (en) * | 2001-09-04 | 2001-09-27 | Life Therapeutics Limited | Renal dialysis |
| US8337444B2 (en) * | 2001-05-22 | 2012-12-25 | Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California | Measurement of cardiac output and blood volume by non-invasive detection of indicator dilution for hemodialysis |
| RU2212029C1 (ru) | 2001-12-03 | 2003-09-10 | Общество с ограниченной ответственностью "Клиника экстракорпоральной гемокоррекции" | Способ анализа жидкой биологической среды в процессе мониторинга |
| US7427508B2 (en) | 2003-10-09 | 2008-09-23 | Organotek Defense System Corporation | Method for assaying multi-component mixtures |
| WO2005069737A2 (en) * | 2004-01-27 | 2005-08-04 | Ramot At Tel Aviv University Ltd. | Method and system for detecting analytes |
| EP1751523B1 (en) | 2004-05-13 | 2017-10-04 | NarTest AS | A portable device and method for on-site detection and quantification of drugs |
| US7966051B2 (en) * | 2005-01-11 | 2011-06-21 | Olympus Corporation | Fluorescent agent concentration measuring apparatus, dose control apparatus, administration system, fluorescent agent concentration measuring method, and dose control method |
| DE102005020384A1 (de) * | 2005-05-02 | 2006-11-09 | Therainvention Gmbh | Spektroskopisches Verfahren zum Nachweis von Analyten |
| WO2009071102A1 (en) | 2007-12-04 | 2009-06-11 | Tallinn University Of Technology | Optical method and device for measuring concentrations of substances in biological fluids |
-
2011
- 2011-06-28 CN CN2011800323962A patent/CN102985822A/zh active Pending
- 2011-06-28 CA CA2837488A patent/CA2837488C/en active Active
- 2011-06-28 EP EP11740556.3A patent/EP2585830B1/en not_active Not-in-force
- 2011-06-28 JP JP2013517023A patent/JP5957450B2/ja active Active
- 2011-06-28 BR BR112012033625A patent/BR112012033625A2/pt not_active Application Discontinuation
- 2011-06-28 US US13/807,688 patent/US9103789B2/en active Active
- 2011-06-28 NZ NZ60568511A patent/NZ605685A/en unknown
- 2011-06-28 KR KR1020137002066A patent/KR101848527B1/ko active Active
- 2011-06-28 WO PCT/EE2011/000008 patent/WO2012000521A1/en not_active Ceased
- 2011-06-28 AU AU2011274009A patent/AU2011274009B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010053556A1 (en) | 1998-05-08 | 2001-12-20 | Anderson Charles W. | Miniature immuno-optical rapid analyte sensor platform |
| US20030231294A1 (en) | 2002-06-12 | 2003-12-18 | Ramesh Wariar | Optical sensor and method for measuring concentration of a chemical constituent using its intrinsic optical absorbance |
| US20060170914A1 (en) * | 2003-07-03 | 2006-08-03 | Wako Pure Chemical Industries, Ltd. | Specific component measuring method by spectral measurement |
Non-Patent Citations (1)
| Title |
|---|
| Med. Biol. Eng. Comput., Vol. 41, pp. 263-270 (2003.05.01.)* |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011274009B2 (en) | 2016-06-23 |
| WO2012000521A1 (en) | 2012-01-05 |
| EP2585830A1 (en) | 2013-05-01 |
| EP2585830B1 (en) | 2018-04-25 |
| US20130193347A1 (en) | 2013-08-01 |
| CA2837488A1 (en) | 2012-01-05 |
| CN102985822A (zh) | 2013-03-20 |
| BR112012033625A2 (pt) | 2016-10-25 |
| JP2013534630A (ja) | 2013-09-05 |
| US9103789B2 (en) | 2015-08-11 |
| NZ605685A (en) | 2014-10-31 |
| AU2011274009A1 (en) | 2013-01-31 |
| JP5957450B2 (ja) | 2016-07-27 |
| KR20130038347A (ko) | 2013-04-17 |
| CA2837488C (en) | 2021-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101848527B1 (ko) | 생물학적 유체 내 중간 및 단백질 결합 요독의 함량 측정 방법 및 장치 | |
| Henle et al. | Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds | |
| JP6552820B2 (ja) | 患者の治療、好ましくは血液透析、血液透析濾過、および腹膜透析の少なくとも１つを監視する方法および装置 | |
| EP2577270A1 (en) | Method and device for measuring and monitoring concentration of substances in a biological fluid | |
| Naito et al. | Oxidative stress markers | |
| Cuisinier et al. | Changes in plasma and urinary taurine and amino acids in runners immediately and 24 h after a marathon | |
| US20130153474A1 (en) | Apparatus for extracorporeal blood treatment, comprising a measuring device for determining the luminescence of the spent dialysate | |
| Chen et al. | High homocysteine, low vitamin B-6, and increased oxidative stress are independently associated with the risk of chronic kidney disease | |
| Leegsma-Vogt et al. | Utilization of in vivo ultrafiltration in biomedical research and clinical applications | |
| Krapfenbauer et al. | Glycoxidation, and protein and DNA oxidation in patients with diabetes mellitus | |
| WO2022208445A2 (en) | Multiparametric optical method and device for determining uremic solutes, including uremix toxins, in biological fluids | |
| Park et al. | Inhalation exposure to cigarette smoke induces endothelial nitric oxide synthase uncoupling and enhances vascular collagen deposition in streptozotocin-induced diabetic rats | |
| CN202018425U (zh) | 用于测量呼吸气中丙酮的装置 | |
| KR20030014691A (ko) | 환자의 전혈, 혈장 및/또는 혈청에서 알파-옥소알데히드를검출하는 방법 | |
| Zemchenkov et al. | An optoelectronic spectral sensor for monitoring the elimination of uremic markers with low and middle molecular weight during hemodialysis therapy | |
| Holmar et al. | Quantification of indoxyl sulphate in the spent dialysate using fluorescence spectra | |
| Fauaz et al. | Erythrocyte protoporphyrin fluorescence as a potential marker of diabetes | |
| Tankiewicz et al. | Anthranilic acid–uraemic toxin damaged red cell’s membrane | |
| Ali et al. | DETERMINATION OF SERUM CONCENTRATIONS OF HOMOCYSTEINE USING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY FOR PATIENTS WITH DIABETES TYPE 2. | |
| Begovic et al. | Seasonal variations in nutritional status and oxidative stress in patients on hemodialysis: Are they related? | |
| Tomson et al. | Development of a method for optical monitoring of creatinine in the spent dialysate | |
| Atanya | The Effects of Acid-Base Parameters, Oxygen and Heparin on the Ability to Detect Changes in the Blood Status of End-Stage Renal Disease Patients Undergoing Hemodialysis Using Whole Blood-Based Optical Spectroscopy | |
| Lauri et al. | Optical dialysis adequacy monitoring: small uremic toxins and contribution to UV-absorbance studied by HPLC | |
| Birngruber et al. | Dermal Sampling Techniques with a Focus on Dermal Open Flow Microperfusion | |
| Eickel et al. | Phenol as a breath marker for hemodialysis of chronic kidney disease patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20130125 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20150430 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20160518 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170821 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20180328 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20180406 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20180406 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20210401 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230404 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240318 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20250407 Start annual number: 8 End annual number: 8 |